Riik: Holland
keel: hollandi
Allikas: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
ENTECAVIR 1-WATER 1 mg/stuk SAMENSTELLING overeenkomend met ; ENTECAVIR 0,9 mg/stuk
Medicopharm AG Stangenreiterstraße 4 83131 NUßDORF AM INN (DUITSLAND)
J05AF10
ENTECAVIR 1-WATER 1 mg/stuk SAMENSTELLING overeenkomend met ; ENTECAVIR 0,9 mg/stuk
Filmomhulde tablet
CALCIUMCARBONAAT (E 170) ; CARMELLOSE NATRIUM (E 466) ; CITROENZUUR 1-WATER (E 330) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; IJZEROXIDE ROOD (E 172) ; MACROGOL 400 ; NATRIUMSTEARYLFUMARAAT ; SOJAPOLYSACCHARIDEN ; TITAANDIOXIDE (E 171) ; ZETMEEL, GEPREGELATINEERD,
Oraal gebruik
Entecavir
Hulpstoffen: CALCIUMCARBONAAT (E 170); CARMELLOSE NATRIUM (E 466); CITROENZUUR 1-WATER (E 330); HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464); IJZEROXIDE ROOD (E 172); MACROGOL 400; NATRIUMSTEARYLFUMARAAT; SOJAPOLYSACCHARIDEN; TITAANDIOXIDE (E 171); ZETMEEL, GEPREGELATINEERD;
2017-12-04
1 B. PACKAGE LEAFLET 2 PACKAGE LEAFLET: INFORMATION FOR THE USER ENTECAVIR MEDICOPHARM 0.5 MG FILMOMHULDE TABLETTEN ENTECAVIR MEDICOPHARM 1 MG FILMOMHULDE TABLETTEN Entecavir READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Entecavir Medicopharm is and what it is used for 2. What you need to know before you take Entecavir Medicopharm 3. How to take Entecavir Medicopharm 4. Possible side effects 5. How to store Entecavir Medicopharm 6. Contents of the pack and other information 1. WHAT ENTECAVIR MEDICOPHARM IS AND WHAT IT IS USED FOR ENTECAVIR MEDICOPHARM TABLETS ARE ANTI-VIRAL MEDICINES, USED TO TREAT CHRONIC (LONG TERM) HEPATITIS B VIRUS (HBV) INFECTION IN ADULTS. Entecavir Medicopharm can be used in people whose liver is damaged but still functions properly (compensated liver disease) and in people whose liver is damaged and does not function properly (decompensated liver disease). ENTECAVIR MEDICOPHARM TABLETS ARE ALSO USED TO TREAT CHRONIC (LONG TERM) HBV INFECTION IN CHILDREN AND ADOLESCENTS AGED 2 YEARS TO LESS THAN 18 YEARS. ENTECAVIR MEDICOPHARM can be used in children whose liver is damaged but still functions properly (compensated liver disease). Infection by the hepatitis B virus can lead to damage to the liver. Entecavir Medicopharm reduces the amount of virus in your body, and improves the condition of the liver. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENTECAVIR MEDICOPHARM DO NOT TAKE ENTECAVIR MEDICOPHARM • IF YOU ARE ALLERGIC (HYPERSENSITIVE) to entecavir or any of the Lugege kogu dokumenti
1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Entecavir Medicopharm 0.5 mg filmomhulde tabletten Entecavir Medicopharm 1 mg filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Entecavir Medicopharm 0.5 mg film-coated tablets Each tablet contains 0.5 mg entecavir (as monohydrate). Entecavir Medicopharm 1 mg film-coated tablets Each tablet contains 1 mg entecavir (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Entecavir Medicopharm 0.5 mg film-coated tablets White to off white, triangle shaped, approx. 8.7 x 8.40 mm, biconvex film- coated tablets debossed with ‘J' on one side and ‘110’ on other side. Entecavir Medicopharm 1 mg film-coated tablets Pink, triangle shaped, approx. 11.0 x 10.60 mm, biconvex film - coated tablets debossed with 'J' on one side and '111' on other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ADULT INDICATION Treatment of chronic hepatitis B virus (HBV) infection (see section 5.1) in adults with: • compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. • decompensated liver disease (see section 4.4) For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B, see sections 4.2, 4.4 and 5.1. PAEDIATRIC POPULATION Treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to < 18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, and 5.1. 4.2 POSOLOGY AND METHOD OF ADM Lugege kogu dokumenti